Information  X 
Enter a valid email address

Diaceutics PLC (DXRX)


Tuesday 04 May, 2021

Diaceutics PLC

Sale of Shares and Director/PDMR Shareholding

RNS Number : 5098X
Diaceutics PLC
04 May 2021




Diaceutics PLC

("Diaceutics" or the "Company")


Sale of Shares and Director/PDMR Shareholding


Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that on 4 May 2021, Philip White, the Chief Financial Officer of Diaceutics, sold 200,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 123 pence per Ordinary Share. The shares were sold for the purposes of settling a personal tax liability. As a result of the sale, Philip's shareholding is 1,756,389 Ordinary Shares, representing 2.09% of the Company's issued share capital.





Diaceutics PLC

Peter Keeling, Chief Executive Officer

via Alma PR

Philip White, Chief Financial Officer




Cenkos Securities plc (Nominated adviser and broker)

+44 (0)207 397 8900

Callum Davidson / Giles Balleny


Michael Johnson (Sales)




Alma PR

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde


Robyn Fisher

Kieran Breheny




About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries.


About DXRX - The Diagnostic Network®

DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.





Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014


Details of the person discharging managerial responsibilities/person closely associated



Philip White


Reason for notification




Chief Financial Officer


Initial notification/




Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



Diaceutics PLC





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each




Nature of the transaction

Sale of Ordinary Shares


Price(s) and volume(s)










123 p






Date of the transaction

4 May 2021


Place of the transaction

AIM Market of the London Stock Exchange























































This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t